December 7, 2021 — Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging, announced a recent boom for DOTAREM (gadoterate meglumine) injection. DOTAREM’s significant increases come in the face of the continued presence of a pandemic and supply chain disruptions. The company shipped more doses of its flagship MRI contrast agent in October than in any other monthly period since its US release in 2013.
“We are making great strides in the U.S. with our flagship product,” said Thomas McLaughlin, Vice President of North America. “DOTAREM is a trusted solution that supports our commitment to radiologists in the MR suite. There's no doubt that our macrocyclic and ionic molecule has the highest kinetic and thermodynamic stability among currently approved GBCAs.”
Since its release in 1989, DOTAREM (gadoterate meglumine) Injection has been a leading MR contrast agent in Europe, Asia, Africa, the Middle East, and South America. DOTAREM received U.S. Food and Drug Administration (FDA) approval in 2013, becoming the first macrocyclic, ionic gadolinium-based contrast agent (GBCA) in the United States. It has become the No. 2 MR contrast agent in the US and is currently No. 1 in the world, with more than 120 million doses delivered in 70 countries.
The news of DOTAREM’s success follows a long legacy of Guerbet committing itself to the radiology community. In the midst of the COVID-19 crisis in 2020, the company mobilized partners and colleagues across the industry to continue making treatment-critical products available to healthcare professionals. In addition, the organization continually supports the industry with research, education, and development, as is the case in their participation in the annual Radiological Society of North America (RSNA) Conference.
For information: www.guerbet.com/en-us/products-solutions/contrast-agents/dotarem-gadoterate-meglumine-injection/
April 24, 2024 
